novo nordisk q2 2025 earnings report - Is Ozempic maker stock a buy after OpenAI partnership?
Novo Nordisk (NYSE: NVO), the company behind the blockbuster diabetes and weight-loss drug Ozempic, has announced a strategic partnership with OpenAI.
The collaboration will integrate advanced artificial intelligence across its operations, from drug discovery and development to manufacturing, supply chains, distribution, and commercial functions, to accelerate the delivery of improved treatments.
? KEY STATISTICS
Possession: 55% - 45%
Shots on target: 6 - 3
Pass accuracy: 88% - 82%
Corners: 5 - 2
??? POST-MATCH REACTIONS
"We showed great character," said the winning coach. "The team never gave up."
The losing side rued missed opportunities but vowed to come back stronger.